Development of MHC Class I Blocking Peptides to Target Metabolic Dysfunction-Associated Steatohepatitis CD8+ T Cell Activation
V. Adams, S. Sarma, C. K. Hall, A. Kennedy
The paper develops MHC class I blocking peptides to inhibit CD8+ T cell activation in MASH, reducing inflammation and fibrosis.
bioRxiv · Mar 12, 2024 · PreprintImmunology